Login to Your Account

AstraZeneca: $200M Up Front

Moody Market Clips Targacept Despite Major Depression Deal

By Randy Osborne

Friday, December 4, 2009
The deal for Phase II adjunctive depression candidate TC-5214 with Targacept Inc. gives AstraZeneca plc backup if things go poorly for Seroquel-XR in the U.S. and leaves the biotech partner in an enviable cash position, though Wall Street mysteriously failed to rejoice over the second hookup between the two firms. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription